Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Arena Pharmaceuticals (NASDAQ: ARNA)

Organization & Developments: Arena

Parents

2011: How Can San Diego Win the Fight Against Diabesity? Xconomy to Dig Deep on Jan. 27 2011
2011: Orexigen Fails to Win FDA Approval of Obesity Drug, Stock Crashes
2011: Vivus, Obesity Drug Stocks Finally Get Some Good News VVUS ARNA(2013)
2016: Arena Investors Hope Celgene Trial A Harbinger For Future Returns - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
2016: Arena: Belviq Sales Going Bust - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
2016: Arena: Belviq Sales Still Slow - Will Eisai Stick Around? - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
2016: Arena: Muted Belviq Sales And Little Partner Help - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
2018: Arena’s Comeback Continues with $800M Deal for Blood Disease Drug
2018: United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug – Endpoints News
2020: Arena Pharmaceuticals: Humira LOE Coming At Right Time For Potential Blockbuster Etrasimod
Arena Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs
Four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH)
Treatment of ulcerative colitis (UC)